Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1995 1
2018 1
2021 4
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.
Krejci D, Opalka P, Krejci J, Zemanova M, Zemanova P, Kultan J, Fischer O, Skrickova J, Bratova M, Cernovska M, Hrnciarik M, Coupkova H, Hurdalkova K, Barinova M, Koubkova L, Dolezal D, Safanda M, Pesek M, Svaton M. Krejci D, et al. Among authors: opalka p. Anticancer Res. 2021 May;41(5):2597-2603. doi: 10.21873/anticanres.15039. Anticancer Res. 2021. PMID: 33952489
Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer.
Skrickova J, Pesek M, Opalka P, Koubkova L, Zemanova M, Hrnciarik M, Blazek J, Svaton M, Krejci J, Coupkova H, Dolezal D, Tuzova T, Holubec L, Mahadevia P, Sandstrom K, Kunovszki P, Barinova M, Hurdalkova K, Fischer O, Cernovska M, Bratova M. Skrickova J, et al. Among authors: opalka p. Anticancer Res. 2021 Nov;41(11):5625-5634. doi: 10.21873/anticanres.15378. Anticancer Res. 2021. PMID: 34732435
Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry.
Venclicek O, Skrickova J, Brat K, Fischer O, Havel L, Hrnciarik M, Marel M, Opalka P, Krakorova G, Rozsivalova D, Kultan J, Mullerova A, Zarnayova L, Smickova P, Vasakova M, Gyorfy Z, Jirousek M, Krejci D, Krejci J, Zuna P, Svaton M, Hrda K, Duba J, Alahakoon J, Svoboda M, Silar J. Venclicek O, et al. Among authors: opalka p. Anticancer Res. 2021 Nov;41(11):5549-5556. doi: 10.21873/anticanres.15368. Anticancer Res. 2021. PMID: 34732425